Advancing Botanical Drug Development Act of 2026

This legislation addresses the significant challenges in developing botanical drugs, which are naturally derived medicines capable of targeting multiple biological pathways for complex chronic and age-related diseases. Despite their scientific and therapeutic potential, only a limited number of botanical drugs have received FDA approval since the regulatory pathway was established in 2004. This is largely due to unique scientific and manufacturing hurdles, such as the natural variability of plant-derived raw materials and the need for extensive sourcing controls and standardization processes, which increase development costs and commercial uncertainty. To stimulate innovation and overcome these barriers, the bill proposes a **12-year period of market exclusivity** for new botanical drugs approved by the FDA. This exclusivity would prevent generic or abbreviated applications from becoming effective for that duration, offering developers a protected period to recoup their investments. By providing tailored incentives, the bill aims to encourage the research and development of safe, effective, multi-target botanical treatments, ultimately expanding options for patients suffering from chronic and age-related diseases and promoting biomedical innovation.